Overview

Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

Status:
Completed

Trial end date:
2017-04-27

Target enrollment:

Participant gender:

Summary

To evaluate the early onset of efficacy of vortioxetine 17 mg intravenously (IV) and vortioxetine 10 mg/day oral dose regimen versus placebo IV and vortioxetine 10 mg/day oral dose regimen on depressive symptoms

Phase:

Phase 2

Details

Lead Sponsor:

H. Lundbeck A/S

Collaborator:

Takeda

Treatments:

Vortioxetine